PULMONX CORP

Pulmonx Corp (NASDAQ: LUNG) trades above its 200‑day SMA, poised for a Q3 2027 bronchoscopic valve launch and early FDA COPD approval that could boost revenue and investor returns.

Pulmonx stock slides 12% amid weak demand and limited liquidity, as investors weigh a stalled pipeline and fierce competition in the pulmonary device market.